vs
BXP, Inc.（BXP）与豪洛捷（HOLX）财务数据对比。点击上方公司名可切换其他公司
豪洛捷的季度营收约是BXP, Inc.的1.2倍（$1.0B vs $872.1M），豪洛捷净利率更高（17.1% vs 15.3%，领先1.8%），豪洛捷同比增速更快（2.5% vs 0.8%），过去两年豪洛捷的营收复合增速更高（1.5% vs 1.3%）
BXP是美国头部商业地产投资信托企业，核心业务为持有、运营及开发A级高端写字楼资产，项目覆盖纽约、波士顿、旧金山等美国核心都市圈，服务企业、科技、专业服务等领域的多元租户。
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
BXP vs HOLX — 直观对比
营收规模更大
HOLX
是对方的1.2倍
$872.1M
营收增速更快
HOLX
高出1.7%
0.8%
净利率更高
HOLX
高出1.8%
15.3%
两年增速更快
HOLX
近两年复合增速
1.3%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $872.1M | $1.0B |
| 净利润 | $133.0M | $179.1M |
| 毛利率 | — | 56.0% |
| 营业利润率 | — | 22.6% |
| 净利率 | 15.3% | 17.1% |
| 营收同比 | 0.8% | 2.5% |
| 净利润同比 | 53.0% | -10.9% |
| 每股收益（稀释后） | $1.69 | $0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BXPHOLX
| Q1 26 | $872.1M | — | ||
| Q4 25 | $877.1M | $1.0B | ||
| Q3 25 | $871.5M | $1.0B | ||
| Q2 25 | $868.5M | $1.0B | ||
| Q1 25 | $865.2M | $1.0B | ||
| Q4 24 | $858.6M | $1.0B | ||
| Q3 24 | $859.2M | $988.0M | ||
| Q2 24 | $850.5M | $1.0B |
净利润BXPHOLX
| Q1 26 | $133.0M | — | ||
| Q4 25 | $248.4M | $179.1M | ||
| Q3 25 | $-121.7M | $187.2M | ||
| Q2 25 | $89.0M | $194.9M | ||
| Q1 25 | $61.2M | $-17.4M | ||
| Q4 24 | $-228.9M | $201.0M | ||
| Q3 24 | $83.6M | $178.6M | ||
| Q2 24 | $79.6M | $194.5M |
毛利率BXPHOLX
| Q1 26 | — | — | ||
| Q4 25 | 58.8% | 56.0% | ||
| Q3 25 | 59.3% | 55.6% | ||
| Q2 25 | 59.2% | 56.3% | ||
| Q1 25 | 59.2% | 37.5% | ||
| Q4 24 | 59.7% | 56.8% | ||
| Q3 24 | 59.5% | 56.4% | ||
| Q2 24 | 59.8% | 55.4% |
营业利润率BXPHOLX
| Q1 26 | — | — | ||
| Q4 25 | — | 22.6% | ||
| Q3 25 | — | 22.6% | ||
| Q2 25 | — | 24.9% | ||
| Q1 25 | — | -0.7% | ||
| Q4 24 | — | 22.5% | ||
| Q3 24 | — | 23.3% | ||
| Q2 24 | — | 24.1% |
净利率BXPHOLX
| Q1 26 | 15.3% | — | ||
| Q4 25 | 28.3% | 17.1% | ||
| Q3 25 | -14.0% | 17.8% | ||
| Q2 25 | 10.2% | 19.0% | ||
| Q1 25 | 7.1% | -1.7% | ||
| Q4 24 | -26.7% | 19.7% | ||
| Q3 24 | 9.7% | 18.1% | ||
| Q2 24 | 9.4% | 19.2% |
每股收益（稀释后）BXPHOLX
| Q1 26 | $1.69 | — | ||
| Q4 25 | $1.56 | $0.79 | ||
| Q3 25 | $-0.77 | $0.84 | ||
| Q2 25 | $0.56 | $0.86 | ||
| Q1 25 | $0.39 | $-0.08 | ||
| Q4 24 | $-1.46 | $0.87 | ||
| Q3 24 | $0.53 | $0.75 | ||
| Q2 24 | $0.51 | $0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $512.8M | $2.4B |
| 总债务越低越好 | — | $2.5B |
| 股东权益账面价值 | $7.7B | $5.2B |
| 总资产 | $25.1B | $9.2B |
| 负债/权益比越低杠杆越低 | — | 0.48× |
8季度趋势，按日历期对齐
现金及短期投资BXPHOLX
| Q1 26 | $512.8M | — | ||
| Q4 25 | $1.5B | $2.4B | ||
| Q3 25 | $861.1M | $2.2B | ||
| Q2 25 | $447.0M | $1.9B | ||
| Q1 25 | $398.1M | $1.6B | ||
| Q4 24 | $1.3B | $2.0B | ||
| Q3 24 | $1.4B | $2.3B | ||
| Q2 24 | $685.4M | $2.4B |
总债务BXPHOLX
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B |
股东权益BXPHOLX
| Q1 26 | $7.7B | — | ||
| Q4 25 | $5.1B | $5.2B | ||
| Q3 25 | $5.0B | $5.0B | ||
| Q2 25 | $5.3B | $4.8B | ||
| Q1 25 | $5.3B | $4.6B | ||
| Q4 24 | $5.4B | $4.8B | ||
| Q3 24 | $5.8B | $5.1B | ||
| Q2 24 | $5.8B | $5.0B |
总资产BXPHOLX
| Q1 26 | $25.1B | — | ||
| Q4 25 | $26.2B | $9.2B | ||
| Q3 25 | $26.0B | $9.0B | ||
| Q2 25 | $25.6B | $8.8B | ||
| Q1 25 | $25.4B | $8.5B | ||
| Q4 24 | $26.1B | $8.7B | ||
| Q3 24 | $26.4B | $9.2B | ||
| Q2 24 | $25.5B | $8.9B |
负债/权益比BXPHOLX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $229.9M |
| 自由现金流经营现金流 - 资本支出 | — | $215.2M |
| 自由现金流率自由现金流/营收 | — | 20.5% |
| 资本支出强度资本支出/营收 | 1.5% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | — | $1.0B |
8季度趋势，按日历期对齐
经营现金流BXPHOLX
| Q1 26 | — | — | ||
| Q4 25 | $407.8M | $229.9M | ||
| Q3 25 | $274.2M | $355.1M | ||
| Q2 25 | $353.1M | $343.3M | ||
| Q1 25 | $210.0M | $169.4M | ||
| Q4 24 | $383.7M | $189.3M | ||
| Q3 24 | $286.1M | $367.0M | ||
| Q2 24 | $367.1M | $405.8M |
自由现金流BXPHOLX
| Q1 26 | — | — | ||
| Q4 25 | $362.7M | $215.2M | ||
| Q3 25 | $231.6M | $341.4M | ||
| Q2 25 | $281.5M | $330.5M | ||
| Q1 25 | $152.6M | $153.9M | ||
| Q4 24 | $312.5M | $172.5M | ||
| Q3 24 | $234.5M | $350.6M | ||
| Q2 24 | $332.4M | $385.3M |
自由现金流率BXPHOLX
| Q1 26 | — | — | ||
| Q4 25 | 41.4% | 20.5% | ||
| Q3 25 | 26.6% | 32.5% | ||
| Q2 25 | 32.4% | 32.3% | ||
| Q1 25 | 17.6% | 15.3% | ||
| Q4 24 | 36.4% | 16.9% | ||
| Q3 24 | 27.3% | 35.5% | ||
| Q2 24 | 39.1% | 38.1% |
资本支出强度BXPHOLX
| Q1 26 | 1.5% | — | ||
| Q4 25 | 5.1% | 1.4% | ||
| Q3 25 | 4.9% | 1.3% | ||
| Q2 25 | 8.2% | 1.3% | ||
| Q1 25 | 6.6% | 1.5% | ||
| Q4 24 | 8.3% | 1.6% | ||
| Q3 24 | 6.0% | 1.7% | ||
| Q2 24 | 4.1% | 2.0% |
现金转化率BXPHOLX
| Q1 26 | — | — | ||
| Q4 25 | 1.64× | 1.28× | ||
| Q3 25 | — | 1.90× | ||
| Q2 25 | 3.97× | 1.76× | ||
| Q1 25 | 3.43× | — | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | 3.42× | 2.05× | ||
| Q2 24 | 4.61× | 2.09× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BXP
| Lease | $818.2M | 94% |
| Parking and other | $30.8M | 4% |
| Development and management services | $9.2M | 1% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
